Radicava was approved in Japan in 2015 and by the FDA in 2017 to treat ALS though presumably most of the research for it occurred long before then. It costs $1

Radicava was approved in Japan in 2015 and by the FDA in 2017 to treat ALS though presumably most of the research for it occurred long before then. It costs $145000 per year in the US and $35000 per year in Japan. It slows down the progression of the disease in a specific subset of patients (early stages of the disease with rapid progression of symptoms) which comprises approximately 7% of people with ALS. Trials among a general ALS population failed to show any efficacy. https://www.healthnewsreview.org/2017/09/facts-about-the-new-als-drug-radicava-that-youre-unlikely-to-see-in-news-stories/ https://www.healthnewsreview.org/2017/09/facts-about-the-new...